Aurobindo Pharma Ltd has received final approval from the US Food & Drug Administration (USFDA) to manufacture and market Valsartan Tablets.
The product is ready for launch, the Hyderabad based company said in release on Tuesday.
Valsartan tablets are the generic equivalent to the reference listed drug product (RLD) Diovan of Novartis Pharmaceuticals Corporation (Novartis) and indicated for the treatment of hypertension, to lower blood pressure.
The product falls under the therapeutic category of CVS (Cardio Vascular) has a market size of approximately US$ 2 billion for the twelve months ending October 2014 according to IMS, according to a release.